Rudman Christian, Viljoen Michelle, Rheeders Malie
>Centre of Excellence for Pharmaceutical Services (PharmaCen), Division of Pharmacology, North-West University, Private Bag X6001, Potchefstroom 2520, South Africa.
>Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Faculty of Natural Sciences, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa.
Afr Health Sci. 2020 Jun;20(2):549-559. doi: 10.4314/ahs.v20i2.2.
Greater access and prolonged exposure to ART may inevitably lead to more treatment failure and increase the need for third-line ART (TLART) in a resource-limited setting.
To describe characteristics and resistance patterns of adult patients initiated on TLART in three districts of the North West province.
All-inclusive retrospective descriptive investigation. Demographics and clinical variables were recorded from adult patient health records (2002-2017) and analysed.
21 Patients (17 females, 4 males) with median (IQR) age of 34 years (30.2-37.8) at HIV diagnosis and 45 years (39.5-47) at TLART initiation were included. Median duration (days) from HIV diagnosis to first-line ART initiation was 101 (37-367), treatment duration on first-line, second-line and between second-line failure and TLART initiation were: 1 269 (765-2 343); 1 512 (706-2096) and 71 (58-126) days respectively.High-level resistance most prevalent were: nelfinavir/r (85.7%), indinavir/r (80.9%), lopinavir/r (76.2%), emtricitabine and lamivudine (95.2%), nevirapine (76.2%) and efavirenz (71.4%). Resistance to 3 major PI mutations in 95% of patients and cross resistance were documented extensively.
This study support the need for earlier resistance testing. It firstly reported on time duration post diagnosis on various ART regimens and secondly resistance patterns of adults before TLART was initiated in these districts.
在资源有限的环境中,更多人能够获得抗逆转录病毒治疗(ART)且治疗时间延长,可能不可避免地导致更多治疗失败,并增加对三线抗逆转录病毒治疗(TLART)的需求。
描述西北省三个地区开始接受TLART治疗的成年患者的特征和耐药模式。
全面的回顾性描述性调查。从成年患者的健康记录(2002 - 2017年)中记录人口统计学和临床变量并进行分析。
纳入21例患者(17例女性,4例男性),HIV诊断时的中位(IQR)年龄为34岁(30.2 - 37.8岁),开始TLART治疗时的年龄为45岁(39.5 - 47岁)。从HIV诊断到开始一线ART治疗的中位持续时间(天)为101天(37 - 367天),一线、二线治疗持续时间以及二线治疗失败与开始TLART治疗之间的持续时间分别为:1269天(765 - 2343天);1512天(706 - 2096天)和71天(58 - 126天)。最常见的高水平耐药情况为:奈非那韦/r(85.7%)、茚地那韦/r(80.9%)、洛匹那韦/r(76.2%)、恩曲他滨和拉米夫定(95.2%)、奈韦拉平(76.2%)和依非韦伦(71.4%)。95%的患者对3种主要蛋白酶抑制剂(PI)突变具有耐药性,并且广泛记录了交叉耐药情况。
本研究支持进行早期耐药性检测的必要性。它首先报告了各种抗逆转录病毒治疗方案诊断后的持续时间,其次报告了这些地区成年患者开始TLART治疗前的耐药模式。